Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was down 4.7% during mid-day trading on Friday . The company traded as low as $9.63 and last traded at $9.74. Approximately 48,133 shares changed hands during trading, a decline of 40% from the average daily volume of 80,171 shares. The stock had previously closed at $10.22.

Analyst Ratings Changes

Separately, Noble Financial began coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating on the stock.

Gyre Therapeutics Price Performance

The firm’s 50-day simple moving average is $11.31 and its 200 day simple moving average is $12.20.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). The business had revenue of $27.87 million for the quarter, compared to analyst estimates of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Insider Transactions at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 38,054 shares of company stock valued at $431,857 in the last three months. 19.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in shares of Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after acquiring an additional 913 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after purchasing an additional 918 shares during the period. Barclays PLC grew its position in Gyre Therapeutics by 13.5% during the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after purchasing an additional 1,389 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.